Teva has received FDA approval for Tobramycin Inhalation Solution, the generic version of Novartis‘ TOBI. TOBI is approved for the management of cystic fibrosis in patients with Pseudomonas aeruginosa.
Tobramycin Inhalation Solution, an aminoglycoside antibiotic, becomes concentrated in the airways when inhaled. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventually cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa.
Teva expects to launch this product in late November 2013.
For more information call (888) 838-2872 or visit Tevagenerics.com.